Effects of adiposity on the human plasma proteome: Observational and Mendelian randomization estimates

Competing Interest Statement

John Danesh sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018).

Funding Statement

Funding: This publication is the work of the authors who are guarantors for its contents. LJG is funded by the University of Bristol alumni on the 4-year BHF Integrative Cardiovascular Science PhD programme. JAB is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). DAH and LJC are funded by the Wellcome Trust (202802/Z/16/Z). KW is supported by the Wellcome Trust. GDS works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1). NS is supported by the Wellcome Trust, British Heart Foundation and NIHR funding to the Cambridge Bioresource. JD is funded by the National Institute for Health Research (Senior Investigator Award). IH is supported by the EPSRC Prostanoid programme (EP/M012530/1) and BHF (PG/16/3/31833). NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC_UU_12013/3) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was funded in whole, or in part, by the Wellcome Trust (202802/Z/16/Z). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by Cambridge (East) Research Ethics Committee. Access to the data was granted by the Data Access Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes